Q2 FY2026 · ended Apr 30, 2026 · Revenue $2.58M, +124.6% YoY · Filed Jun 15, 2026
Zeo Scientifix, Inc (ZEOX) files with the SEC under industry code 2836, Biological Products, (No Diagnostic Substances). In Q2 of fiscal 2026, the quarter ended Apr 30, 2026, it reported revenue of $2.6 million and a net loss of $145,000. Free cash flow was -$202,000. As of Jun 30, 2026 it held $2.3 million in cash and investments and $337,000 in total debt.
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- ZEOX (OTC)
- Fiscal year ends
- June 30
- Incorporated in
- NV
- Headquarters
- Davie, FL
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1557376
- Former names
- Organicell Regenerative Medicine, Inc. (until Jan 29, 2024); Biotech Products Services & Research, Inc. (until Jun 15, 2018); BESPOKE TRICYCLES INC (until Sep 14, 2015)
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q2 FY2026 Apr 30, 2026 |
Q1 FY2026 Jan 31, 2026 |
Q3 FY2025 Jul 31, 2025 |
Q2 FY2025 Apr 30, 2025 |
Q1 FY2025 Jan 31, 2025 |
|---|---|---|---|---|---|
| Revenue | $2.6M | $1.4M | $1.3M | $1.1M | $1.1M |
| Operating income | -$512,000 | -$878,000 | -$2.1M | -$1.4M | -$1.3M |
| Net income | -$145,000 | -$852,000 | -$2.1M | -$1.4M | -$1.2M |
| Diluted EPS | -$0.02 | -$0.12 | -$0.32 | -$0.22 | -$0.20 |
| Operating cash flow | -$138,000 | -$471,000 | -$257,000 | -$143,000 | $65,000 |
| Free cash flow | -$202,000 | -$485,000 | -$280,000 | — | — |
| Total assets | $3.9M | $2.6M | $1.7M | $1.4M | $1.6M |
| Total liabilities | $3.2M | $3.0M | $4.0M | $3.5M | $3.4M |
| Stockholders' equity | $712,000 | -$383,000 | -$2.3M | -$2.1M | -$1.8M |
| Cash and investments | $1.8M | $1.0M | $314,000 | $542,000 | $720,000 |
| Total debt | $343,000 | $349,000 | $817,000 | $712,000 | $691,000 |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Other events
|
Nov 3, 2026 | Nov 3, 2026 |
| 8-K |
Current report
Material agreement, Unregistered share sale
|
Oct 30, 2026 | Oct 26, 2026 |
| 8-K |
Current report
Material agreement
|
Oct 26, 2026 | Oct 26, 2026 |
| 10-KT | Transition report | Oct 13, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Bylaw or fiscal year change
|
Sep 15, 2026 | Sep 10, 2026 |
| 8-K |
Current report
Other events
|
Sep 15, 2026 | Sep 15, 2026 |
All 518 Zeo Scientifix, Inc SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.